Benzinga | Jun 15, 2021 07:31AM EDT

Ocugen Announces Jubilant HollisterStier As Manufacturing Partner For US Production Of COVID-19 Vaccine Candidate, COVAXIN

Ocugen, Inc. (NASDAQ:OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19, today announced that it has selected Jubilant HollisterStier of Spokane, Washington as its manufacturing partner for COVAXIN(tm) to prepare for potential commercial manufacturing of COVAXIN(tm) for the US and Canadian markets.



"We are fully committed to bringing COVAXIN to the US and Canadian markets because we believe it has the potential to save lives by adding a weapon to the arsenal in the fight against emerging variants," said J.P. Gabriel, Ocugen's Senior Vice President, Manufacturing and Supply Chain. "Securing US-based manufacturing capability is a critical step as we prepare to submit our regulatory submissions to the FDA and Health Canada. Based on Bharat Biotech's strong track record of developing and commercializing vaccines globally and Jubilant's proven track record in manufacturing, we are well-prepared to transition US manufacturing of COVAXIN to our new partner."

"We are excited to expand our basket of vaccine products and meet the increasing demand from our customers for COVID-19 vaccines in the US," said Amit Arora, President Jubilant HollisterStier.

"We are pleased to partner with Ocugen and support the ongoing fight against COVID-19. With two facilities in North America working to manufacture multiple COVID-19 vaccines and therapies, we remain committed to supporting efforts to eradicate this global pandemic," stated Pramod Yadav, CEO Jubilant Pharma Limited.